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The most prevalent cause of nosocomial bloodstream infection (BSI) among
non-C. albicans Candida species, Candida parapsilosis, may not only be resistant to
azole antifungal agents but also disseminate to vulnerable patients. In this survey
of BSIs occurring at a large Italian hospital between May 2014 and May 2019, C.
parapsilosis accounted for 28.5% (241/844) of allCandida isolates causing BSI episodes.
The majority of episodes (151/844) occurred in medical wards. Across the 5 yearly
periods, the rates of azole non-susceptibility were 11.8% (4/34), 17.8% (8/45), 28.6%
(12/42), 32.8% (19/58), and 17.7% (11/62), respectively, using the Sensititre YeastOne®
method. Among azole non-susceptible isolates (54/241; 22.4%), 49 were available for
further investigation. Using the CLSI reference method, all 49 isolates were resistant
to fluconazole and, except one (susceptible dose-dependent), to voriconazole. Forty
(81.6%) isolates harbored the Erg11p Y132F substitution and nine (18.4%) isolates the
Y132F in combination with the Erg11p R398I substitution. According to their genotypes,
as defined using a microsatellite analysis based on six short tandem repeat markers,
87.7% of isolates (43/49) grouped in two major clusters (II and III), whereas 4.1% of
isolates (2/49) belonged to a separate cluster (I). Interestingly, all the isolates from cluster
II harbored the Y132F substitution, and those from cluster III harbored both Y132F and
R398I substitutions. Of 56 non-Italian isolates included as controls, two Indian isolates
with the Y132F substitution had a genotype clearly differing from that of the isolates
from clusters II and I. In conclusion, these findings show the dominance of clonal Y132F
isolates in our hospital and suggest detection of the Y132F substitution as helpful tool to
prevent transmission among hospitalized patients at risk of BSI.
Keywords: bloodstream infections, Candida parapsilosis, antifungal susceptibility, azole resistance, microsatellite
genotyping, molecular clones
Martini et al. Azole-Resistant Candida parapsilosis Clones
INTRODUCTION
Among non-C. albicans Candida (NCAC) species (Miceli et al.,
2011), Candida parapsilosis has emerged as a common cause
of bloodstream infection (BSI), which represents—together
with other forms of invasive candidiasis (i.e., non-candidemia
forms)—themost prevalent systemic fungal nosocomial infection
(Kullberg and Arendrup, 2015; Mesini et al., 2020). Although
the prevalence of NCAC species may vary considerably
depending on geographical location (Lamoth et al., 2018), C.
parapsilosis remains the second or third (after Candida albicans)
most frequently isolated Candida species from hospitalized
patients globally (Guinea, 2014). For instance, a 9-year hospital
laboratory-based survey of BSI cases published in 2015 (Posteraro
et al., 2015) showed that C. parapsilosis complex—including
C. parapsilosis and its two closely related species Candida
metapsilosis and Candida orthopsilosis (Tavanti et al., 2005)—
accounted for ∼21% (262/1,250) of all Candida-driven and non-
Candida-driven BSIs (second most common after C. albicans).
Similarly, Govender et al. (2016) surveyed 2,172 cases of
candidemia from a 19-month period in public sector or private-
sector hospitals across South Africa, showing that C. parapsilosis
was responsible for 35% of public-sector cases (second most
common after C. albicans) and >50% in the private sector
(outranking C. albicans).
While C. parapsilosis BSIs generally result in lower morbidity
and mortality rates than C. albicans BSIs (Tóth et al., 2019), the
dissemination of C. parapsilosis from healthcare environments to
vulnerable patients is troubling (Lamoth et al., 2018), as is the
increasing resistance to azole antifungal drugs (Thomaz et al.,
2018; Pristov and Ghannoum, 2019). Only 199 (37%) of 531 C.
parapsilosis isolates in the survey by Govender et al. (2016) were
susceptible to the triazoles fluconazole and voriconazole, whereas
only 18 (7%) of 262 C. parapsilosis isolates in the survey by
Posteraro et al. (2015) were non-susceptible [12 susceptible dose-
dependent (SDD) and six resistant] to fluconazole. Furthermore,
two (0.8%) of 262 isolates in the study by Posteraro et al.
(2015) were non-susceptible (all SDD) to voriconazole, whereas
123 (44%) of 282 fluconazole-resistant isolates in the study
by Govender et al. (2016) were also resistant to voriconazole.
Altogether, these findings suggest that triazole non-susceptible C.
parapsilosis could significantly affect the management of patients
with candidemia (Pappas et al., 2016) by limiting the choice of
antifungal agents (Eschenauer et al., 2015).
Unlike other NCAC species, C. parapsilosis has historically
been associated with neonates (Pammi et al., 2013) and
the use of high-glucose containing parenteral nutrition
(Pereira et al., 2015), which strongly correlates with the
species’s abilities of colonizing implanted medical devices (e.g.,
intravascular catheters) and, consequently, thriving in certain
clinical settings (Asadzadeh et al., 2019). The adherence of C.
parapsilosis to both abiotic and biotic surfaces is a key stage
for host colonization and/or biofilm formation (Priest and
Lorenz, 2015). This implies that the matrix beta-glucans in
biofilms formed by C. parapsilosis—the second in producing
biofilm among Candida species (Soldini et al., 2018)—would
sequester multiple types of antifungals (i.e., amphotericin B
and fluconazole), hence contributing to the persistence of
antifungal-recalcitrant C. parapsilosis infections (Pristov and
Ghannoum, 2019). Interfering with beta-glucan synthesis,
echinocandins (lipopeptidic antifungals) would represent the
practical answer for C. albicans and NCAC isolates that are
resistant to azoles (Whaley et al., 2017). However, prolonged
exposure to echinocandins may enable C. parapsilosis to not only
develop antifungal resistance (Papp et al., 2018) but to cross-
infect several patients—perhaps through healthcare workers
via hand carriage—hence leading to its high isolation rate (van
Asbeck et al., 2009).
As the epidemiology of C. parapsilosis is more complex
than that might be expected from its pathobiology (Priest
and Lorenz, 2015), it has become essential to determine the
genetic relatedness among C. parapsilosis isolates when clusters
appear (van Asbeck et al., 2009). It should also be essential
to investigate clustered C. parapsilosis isolates for the presence
of point mutations in the ERG11 gene when azole resistance
appears (Pristov and Ghannoum, 2019). Until recently, data
documented the Y132F amino acid substitution in ERG11p—the
ERG11-encoded enzyme lanosterol 14-α-demethylase—as the
prevalent fluconazole resistance mechanism in isolates (mainly
bloodstream isolates) of C. parapsilosis worldwide (Grossman
et al., 2015; Asadzadeh et al., 2017; Choi et al., 2018; Magobo
et al., 2020). Surprisingly, an Indianmulticenter laboratory-based
surveillance study revealed that in many centers in Delhi and a
single center in South India, the K143R amino acid substitution
was most prevalent as a single resistance mechanism in either
bloodstream or non-bloodstream isolates ofC. parapsilosis (Singh
et al., 2019).
Here we report a retrospective analysis of azole-resistant C.
parapsilosis isolates, recovered from BSIs over a 5-year period
in a large Italian university hospital, aimed at defining their
prevalence, their underlying molecular mechanism, and their
clonal distribution among different hospital wards.
MATERIALS AND METHODS
Study Setting and Clinical Isolates
The study was retrospectively conducted at the Policlinico
Universitario A. Gemelli IRCCS of Rome—a 1,500-bed tertiary
care university teaching hospital—using C. parapsilosis isolates
consecutively collected from blood cultures of patients, who
were diagnosed with fungal BSI between May 2014 and May
2019 and were retrieved through a search of the clinical
microbiology laboratory information system. Isolates were from
single episodes of BSI, and were kept frozen in glycerol and
subcultured at the time of this study. Before testing, isolates
were identified to the species level (i.e., as C. parapsilosis sensu
stricto, hereafter referred to as C. parapsilosis) by matrix-assisted
laser desorption/ionization time-of flight mass spectrometry as
previously described (De Carolis et al., 2014). Another 56 C.
parapsilosis control isolates were from hospitalized patients in
non-Italian countries, namely Austria (n = 8), Brazil (n = 8),
Greece (n = 8), India (n = 8), Iran (n = 8), Kuwait (n = 8),
and the Netherlands (n= 8). As shown in Table S1, we provided
detailed information for all the isolates, whereas the measured
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antifungal minimum inhibitory concentration (MIC) values were
not available except for Italian isolates (see below).
The study did not require oversight by the institutional ethics
committee because the descriptive nature implied only samples
that were obtained during routine laboratory activity.
Antifungal Susceptibility Testing
For all the C. parapsilosis isolates included in this study, MIC
values were determined against amphotericin B, fluconazole,
itraconazole, posaconazole, voriconazole, anidulafungin,
caspofungin, micafungin, and flucytosine, as part of routine
patient care (Posteraro et al., 2015). The antifungal testing
was performed using an adaptation of the Clinical Laboratory
Standards Institute (CLSI) method based on the M27-A3
document (CLSI, 2008), namely the Sensititre YeastOne R©
(SYO) method (Thermo Fisher Scientific, Cleveland, OH,
USA). We obtained MIC values by visual inspection of the
SYO microdilution broth panels following 24 h of incubation
at 35◦C, and we calculated MIC50, MIC90, and ranges using
GraphPad Prism 7. We interpreted MIC results according
to clinical breakpoints (CBPs) reported in the CLSI M27-S4
document (CLSI, 2012). In particular, for fluconazole, isolates
with MIC ≥8µg/mL were defined as resistant and those
with MIC of 4µg/mL as SDD; for voriconazole, isolates with
MIC of ≥1µg/mL were defined as resistant and those with
MIC of 0.25–0.5µg/mL as SDD. Additionally, we applied the
24-h epidemiological cutoff values (ECVs) of amphotericin B,
triazoles (fluconazole, itraconazole, posaconazole, voriconazole),
echinocandins (anidulafungin, caspofungin, and micafungin),
and flucytosine established for the SYO method and C.
parapsilosis or other five Candida species (Cantón et al., 2012,
2013). Subsequently, the isolates that were either non-susceptible
(resistant or SDD/intermediate) or that had non-wild-type
(NWT) susceptibility (MIC > ECV) to one or more of the
azoles were rechecked for antifungal susceptibility against only
fluconazole and voriconazole using the above-mentioned CLSI
method, with the two azole antifungals prepared and used as
reported in the M27-S4 document (CLSI, 2012).
DNA Isolation
Genomic DNA from C. parapsilosis isolates was obtained with
material/equipment of Roche Diagnostics GmbH (Mannheim,
Germany). Briefly, we suspended each isolate in 400-µL MagNA
Pure Bacteria Lysis Buffer in a tube prefilled with ceramic beads
(MagNA Lyser Green Beads), and we used the MagNA Lyser
instrument for 30 s at 6,500 rpm to lyse fungal cells mechanically.
DNA was then extracted and purified using the MagNA Pure LC
instrument with the MagNA Pure DNA isolation kit III (bacteria,
fungi), according to the recommendations of the manufacturer.
ERG11 Gene Amplification and Sequencing
The entire open reading frame of the ERG11 gene was sequenced
for all C. parapsilosis isolates with elevated MICs (i.e., in the
resistant or SDD categories) of fluconazole, as well as for the
Italian fluconazole-susceptible isolates included in the multilocus
microsatellite typing analysis (see below). To this end, we used
genomic DNA obtained as above described for PCR amplification
with a pair of primers specifically designed by Souza et al.
(2015) and shown in Table 1. The resulting PCR products were
purified with the MinElute PCR Purification Kit (QIAGEN,
Hilden, Germany) and sequenced using an ABI PRISM 3130xl
Genetic Analyzer instrument (Applied Biosystems, Palo Alto,
CA, USA). DNA sequences were analyzed with the Chromas
(http://www.technelysium.com/) and MEGA 6.06 (Tamura et al.,
2013) software packages.
Microsatellite Typing
We performed multilocus microsatellite typing using a
previously described panel of six short tandem repeat (STR)
markers, which consisted of three trinucleotide and three
hexanucleotide markers, as described by Diab-Elschahawi
et al. (2012). One of the amplification primers in each STR
panel was labeled with either 6-FAMTM, JOETM, or TAMRATM
(https://www.sigmaaldrich.com/), as shown in Table 1. Two
multiplex PCRs were carried out in a final volume of 25 µL
containing ∼1 ng genomic DNA (see above) as described
previously (Diab-Elschahawi et al., 2012). The resulting PCR
products were analyzed on an automatic sequencer ABI 3500XL
Genetic Analyzer (Applied Biosystems). Copy number of
the STR markers of C. parapsilosis isolates were determined
using GeneMapper Software 5 (Applied Biosystems), and the
combination of allele numbers for all six diploid loci allowed
to define an arbitrary microsatellite genotype (Asadzadeh et al.,
2019). Then, a dendrogram was constructed and the genetic
relationship of the isolates was determined using the minimum-
spanning tree available in the Applied Maths BioNumerics
software 7.6.1 (https://www.applied-maths.com/). According to
Asadzadeh et al. (2019), we considered the isolates possessing the
same alleles for all six diploid loci as having the same genotype
(cluster). Genotypes that differed in only one of six diploid loci
were closely related genotypes. The reference C. parapsilosis
strain CBS6318 (a skin isolate) was included in each run to
ensure the reproducibility of the STR analysis.
RESULTS
Distribution of Isolates Causing BSI
Isolates of C. parapsilosis were from 241 episodes of BSIs that
occurred during the 5-year study period (May 2014–May 2019)
in our Italian hospital. Of these cases, 86 were central venous
catheter-related BSIs. Overall, 151 (62.7%) were from patients
in medical (non-surgical) wards, 46 (19.1%) from patients in
surgical wards, 24 (9.9%) from patients in oncology/hematology
wards, and 20 (8.3%) from patients in intensive care units
(Figure 1). Two hundred twenty patients were adult and 21
patients were pediatric/neonates. Twenty-three patients had
multiple episodes of BSI (defined as episodes due to the same
fungal species that occurred at least >21 days after the first
detected episode). Expectedly (Posteraro et al., 2015), the C.
parapsilosis isolates represented the 28.5% of all the Candida
isolates associated with BSI episodes (n = 844), of which 14.1%
(34/241) in 2014–2015, 18.7% (45/241) in 2015–2016, 17.4%
(42/241) in 2016–2017, 24.1% (58/241) in 2017–2018, and 25.7%
(62/241) in 2018–2019.
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TABLE 1 | Overview of oligonucleotides used as primers in amplification-based methods.
Method Target Sequences (5′-3′) of oligonucleotidesa used as:
Forward primer Reverse primer
ERG11 sequencing Open reading frame (ORF)
Portion 1 CGAGATAATCATCAACGAACATTC CGTTTAAAACATCCAAAGACCTTA
Portion 2 AATCTGAGGGTTTCCTTGATGGT AAAGACCGCATTGACTACCGAT







aSequences of the primer pairs used for ERG11 sequencing or microsatellite typing were described in references of Souza et al. (2015) and Diab-Elschahawi et al. (2012), respectively.
bOne of the amplification primers (i.e., the forward primer) was labeled with either 6-FAMTM, JOETM, or TAMRATM.
FIGURE 1 | Temporal distributions of Candida parapsilosis bloodstream infections (BSIs) in different hospital wards by all (total bar height) and fluconazole or
voriconazole non-susceptible (white lines) causative isolates. Overall, BSIs caused by all isolates were 241, whereas those caused by fluconazole non-susceptible
isolates were 54 and those caused by voriconazole non-susceptible isolates were 49 (if considering one antifungal drug regardless of the other). As voriconazole
non-susceptible isolates were also fluconazole non-susceptible (n = 49), the numbers of voriconazole non-susceptible isolates were coincident (one white-line
indicated) or lower (the bottom white-line indicated) than the numbers of fluconazole non-susceptible isolates.
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Azole Antifungal Susceptibilities and
ERG11 Gene Sequences
The MIC results routinely obtained with the SYO method
showed that 53 (22.0%) of 241 C. parapsilosis isolates were
resistant (MICs, ≥8µg/mL; range, 8–128µg/mL) and one
(0.4%) was SDD to fluconazole (MIC = 4µg/mL), while 27
(11.2%) were resistant (MICs, ≥1µg/mL; range, 1–2µg/mL)
and 22 (9.1%) were SDD (MICs, 0.25–0.5µg/mL; range, 0.25–
0.5µg/mL) to voriconazole, according to the CLSI CBPs (CLSI,
2012). None of remaining 187 isolates showed non-susceptibility
or NWT phenotypes to any other antifungal agents tested (data
not shown).
Figure 1 depicts the distribution of C. parapsilosis BSIs
in different wards according to the non-susceptibility (i.e.,
dose-dependent susceptibility or resistance) to fluconazole and
voriconazole of all BSI causative isolates. As shown, the numbers
of azole non-susceptible isolates increased across the study’s
periods, reaching the maximum between May 2017 and May
2018 (n = 19). However, this was evident in medical wards
(10/34) but not in surgery (3/12), oncology/hematology (2/6), or
intensive care wards (4/6). Accordingly, the rates of azole non-
susceptibility were 11.8% (4/34), 17.8% (8/45), 28.6% (12/42),
32.8% (19/58), and 17.7% (11/62), respectively.
Table 2 summarizes the antifungal susceptibility profiles for
49 of 54 azole non-susceptible isolates based on SYO testing.
Five isolates were not included because they were no longer
available. As shown, all 49 isolates were either resistant to
fluconazole or, except one, non-susceptible to voriconazole (26
resistant and 22 SDD), according to the interpretive CLSI
breakpoints. Then, we retested the 49 isolates against fluconazole
and voriconazole using the CLSI reference method. While
differences between SYO and CLSI MICs were always within
one/two 2-fold microdilutions (as expected), the CLSI reference
testing confirmed all 49 isolates to be resistant to fluconazole,
with 48 of them also being cross-resistant to voriconazole.
Indeed, only one isolate (MIC, 0.25µg/mL) remained in the
SDD category, whereas 22 isolates (MICs, 1µg/mL) shifted
to the resistant category when retested against voriconazole
with the CLSI reference method. Consistently, applying the
SYO specific epidemiological cutoff values, all 49 isolates
appeared NWT against both fluconazole and voriconazole
(Table 2), which suggested acquisition of resistance mechanisms
in the isolates.
Therefore, we characterized the 49 isolates for the presence or
absence of point mutation(s) in the ERG11 gene that translated
to amino acid substitution(s) in the Erg11p. Of these isolates,
40 harbored the Y132F substitution and nine the Y132F in
combination with the R398I substitution. As shown in Table S1,
of 56 additional (non-Italian) isolates studied, two isolates (from
India) were resistant to fluconazole and harbored the Y132F
substitution. Of note, all Y132F mutations found in Italian
isolates were due to the same nucleotide substitution (A395T),
whereas searching for other point mutations showed that all
49 Y132F isolates harbored a synonymous substitution (I197I).
Additionally, none of the fluconazole-susceptible Italian isolates
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Microsatellite Analysis of Azole-Resistant
Isolates
A panel of six STR markers for the microsatellite-based typing
allowed the identification of 68 genotypes among 115 C.
parapsilosis isolates, which included 58 Italian isolates (49
fluconazole-resistant and 9 fluconazole-susceptible), 56 non-
Italian isolates (4 fluconazole-resistant and 52 fluconazole-
susceptible), and 1 reference strain (CBS6318; fluconazole-
susceptible) (Table S1). According to their genotypes, almost all
Italian isolates formed three clusters (≥2 identical genotypes
at all loci) with two (cluster I), 35 (cluster II), and eight
(cluster III) isolates, which were recovered from 2, 34, and 7
patients, respectively. Four isolates were recovered from two
patients (2 in cluster II and 2 in cluster III, respectively) during
their two recurrences of BSI episodes (the first and second
episodes in both patients were 1-year elapsed from each other).
Sixty-one genotypes, including the remaining 13 Italian isolates
and 49 of 56 non-Italian isolates, involved only one patient
each. Three other genotypes involved patients from Greece
(three isolates), India (two isolates), and The Netherlands (two
isolates), respectively.
The relationship between the 68 microsatellite genotypes is
depicted in Figures 2, 3. The dendrogram shown in Figure 2
illustrates two major clusters consisting of fluconazole-resistant
isolates (43/49). While all isolates from cluster II harbored
the Y132F substitution, those from cluster III also harbored
the R398I substitution. Interestingly, the other Italian isolates
with Y132F (cluster I, 2 isolates) or Y132F-R398I (one
isolate) substitutions were closely related to cluster II and III,
respectively, while the two Indian isolates with the Y132F
substitution had a clearly different genotype than the isolates
from clusters II and I. As detailed in Figure 2, the main Italian
clusters appeared in the hospital from 2015 (cluster II) or 2016
(cluster III) and persisted until 2019, tending to be most apparent
in 2017 (cluster II, 13/35 isolates) or 2018 (cluster III, 3/8
isolates). Alike, most patients infected by the isolates of cluster
II (19/35) or cluster III (5/8) were from medical wards.
The minimum spanning tree shown in Figure 3 illustrates
the differences between the genotypes based on a categorical
analysis. Among the isolates harboring the Y132F substitution
(40 isolates) and the Y132F-R398I substitution (9 isolates), there
were apparently closely related genotypes that differed in only
one of the six microsatellite markers and comprised, respectively,
2 isolates (cluster I) and 1 isolate (single). Three other single
genotypes differed in two of the six microsatellite markers.
DISCUSSION
This study led to some important observations. First, we
analyzed a large collection of fluconazole-resistant isolates of
C. parapsilosis that were causing BSI in patients from a single
hospital in Italy. These isolates represented almost the totality
of fluconazole-resistant C. parapsilosis BSI episodes recorded by
us between May 2014 and May 2019 and we excluded only
four episodes from our analysis due to unavailability of isolates.
We noted that the frequency of C. parapsilosis isolates found
to be non-susceptible (resistant and SDD) to fluconazole did
vary in the study periods (4/34 < 8/45 < 12/42 < 19/58 >
11/62 isolates), reaching the highest from May 2017 to May
2018. However, significance of this data may be underpowered
because of relatively low numbers, as well as it is difficult to
explain why the frequency of non-susceptible isolates decreased
from May 2018 to May 2019. While C. parapsilosis lately became
the second cause of candidemia in European centers, it yet
remains unclear how the concomitant conditions of the patients,
the interventions they undergo, and the drugs used may have
concurred with the emergence of C. parapsilosis as a bloodstream
pathogen (Silva et al., 2012). Until recently, a population-based
surveillance study conducted in Barcelona (Spain) showed being
a hematologic transplant, having prior fluconazole exposure,
and being of a neonatal age as independent predictors of C.
parapsilosis (and other NCAC) BSI (Rodríguez et al., 2010). In
our study, the majority of C. parapsilosis BSI episodes identified
(i.e., either due to resistant or susceptible isolates) occurred in
adult patients (mainly from medical wards), and only a minority
occurred in pediatric or neonatal patients. The reasons for these
apparently conflicting data are unknown, but it is plausible that a
diversity in antifungal prophylaxis practices or overall incidences
among patient populationsmight explain the differences between
the two studies. Altogether, these observations are consistent
with traits found in C. parapsilosis infections (i.e., candidemia
and other forms of candidiasis), such as nosocomial outbreaks,
horizontal transmission, and resistance to azole antifungal agents
(Pfaller and Castanheira, 2016). While such species-specific traits
complicate our understanding of what makes C. parapsilosis a
serious problem, they may actually hinder the eradication of
infection by and the efficacy of antifungal therapy for hospitalized
patients (Tóth et al., 2019).
Although triazoles continue to be useful for treating C.
parapsilosis infections (Pristov and Ghannoum, 2019), we as
well as other mycologists (Ostrosky-Zeichner and Andes, 2017)
chose to routinely perform the testing of azole susceptibility
for all Candida isolates associated with invasive disease (i.e.,
all bloodstream and other sterile site isolates). Adopting this
strategy allows to monitor the trends of resistance over time
and to track the emergence of isolates with an elevated MIC for
a given antifungal agent. Compared to the study of antifungal
susceptibility profiles of bloodstream yeast isolates during the
years from 2005 to 2013 (Posteraro et al., 2015), we noted that in
the present study, the rates of C. parapsilosis susceptibility (WT
phenotype) to fluconazole and voriconazole decreased over the
years from 92.3 to 77.6%. Therefore, we thought there was value
in assessing the resistance mechanisms via genotypic studies, as
this (from the laboratory perspective) is key to detecting those
molecular changes responsible for the elevated MIC phenotype,
and importantly, the reduced antifungal effect.
We characterized azole resistance mechanisms of 49 C.
parapsilosis isolates with NWT phenotypes to fluconazole
and voriconazole. We found that all isolates had the Y132F
substitution in Erg11p, indicating that the alteration on position
132 in the lanosterol 14-α-demethylase target enzyme may be
mainly responsible for azole resistance in C. parapsilosis. In line
with the findings from studies conducted in the United States
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FIGURE 2 | Dendrogram of similarity based on the microsatellite genotypes from 115 Candida parapsilosis isolates. The scale bar in the upper left corner indicates
the similarity percentages, whereas the columns on the right report details on the 58 Italian isolates. Clusters I–III in the boxes denote those fluconazole-resistant
isolates that harbored an amino acid substitution in the Erg11p, the azole-target enzyme encoded by the ERG11 gene.
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FIGURE 3 | Minimum spanning tree analysis based on the microsatellite genotypes from 115 Candida parapsilosis isolates. Each circle corresponds to a unique
genotype, whereas the sizes of the circles correspond to the numbers of isolates in the same genotype. The lines between the circles represent relative distance
between isolates. The colors of the circles represent in (A) isolates from different hospitals and in (B) isolates harboring or not harboring the Erg11p Y132F (alone or in
combination with the Erg11p R398I) substitution.
(Berkow et al., 2015; Grossman et al., 2015), we detected the
Erg11p Y132F substitution in combination with the Erg11p
R398I substitution, but only for 9 of 49 isolates. The R398I
substitution is unable to confer azole resistance on its own
and seems to be rather a compensatory mutation (Berkow and
Lockhart, 2017). Among the fluconazole and voriconazole NWT
isolates of C. parapsilosis collected worldwide during 2016–
2017 by Castanheira et al. (2019), 37 (80.4%) of 46 isolates
harbored the Y132F substitution and 35 of these isolates (18
in 2016 and 17 in 2017) were from three Italian hospitals, 22
of which were from a single hospital in Genoa. Of note, a
recently conducted study in Italy provided the first evidence
that the Y132F substitution (i.e., the A395T mutation in the
ERG11 gene) confers also multi-azole resistance in clinical
isolates of C. orthopsilosis (Rizzato et al., 2018). Besides altering
the binding site of the enzyme—thus preventing the binding
of azoles—mutation in ERG11 prompts the fungal cell to
develop bypass pathways (i.e., not interrupted by azoles) to
maintain a functional cell membrane (Pristov and Ghannoum,
2019). Thus, alterations in the ergosterol biosynthetic pathway—
together with efflux-pump gene alterations—are central to the
development of azole resistance in C. parapsilosis (Tóth et al.,
2019). Interestingly, resistance to azoles and echinocandins—
C. parapsilosis has a natural polymorphism in the FKS1 gene,
resulting in a decreased sensitivity of the corresponding glucan
synthase to echinocandins—may be linked to single pathways
(Tóth et al., 2019). Recently, a G111R substitution in the
sterol desaturase encoding ERG3 gene was responsible for
altered azole and echinocandin susceptibilities in C. parapsilosis
(Rybak et al., 2017). Nonetheless, the SENTRY antifungal
surveillance program from 1997 to 2016 documented the
sustained activities of fluconazole (azoles) and echinocandins
against invasive isolates of Candida species, confirming that
fluconazole-resistant and echinocandin-resistant C. parapsilosis
isolates remain uncommon (Pfaller et al., 2019).
The emergence of clonal (and non-clonal) resistance in
clinical, or hospital, settings worldwide is of great concern
(Ostrosky-Zeichner and Andes, 2017). An example is Candida
auris, a formidable yeast just owing to its multidrug resistance
(Pristov and Ghannoum, 2019). While the high clonal inter-
and intra-hospital transmission implies C. auris to become
widespread across several countries (de Groot et al., 2020), it
is noteworthy that the Erg11p Y132F substitution has also been
reported in C. auris isolates from India, Pakistan, and Venezuela,
and that these isolates are strongly associated with clonal
transmission (Lockhart et al., 2017; Chowdhary et al., 2018).
However, the Y132F substitution encompassed all isolates as in
our study (100%) or only a part, albeit considerable, as reported
elsewhere—i.e., 31.0–51.0% (Berkow et al., 2015; Grossman
et al., 2015; Souza et al., 2015; Asadzadeh et al., 2017) or
63.8% (Choi et al., 2018)—of fluconazole-resistant C. parapsilosis
isolates. Therefore it is important, when feasible, to consider
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these findings together with those of genotyping analyses that
demonstrate a low genetic diversity among Y132F isolates. Choi
et al. (2018) used microsatellite analysis to reveal that the
proportion of clonal C. parapsilosis isolates was much higher in
the group of fluconazole-resistant isolates harboring the Y132F
substitution (86.7%, 26/30) than in the group of fluconazole-
resistant isolates not harboring the Y132F substitution (11.8%,
2/17). Of note, all the 30 isolates represented four clonal
isolates—based on a genotype resulting from combination of the
sizes of four markers—and persisted within two South Korea
hospitals for several years (Choi et al., 2018). Clonal isolates in
that study were≥2 isolates with identical genotypes according to
microsatellite typing.
The results of microsatellite analysis in our study were
consistent with those of few dominant genotypes identified by
Choi et al. (2018). The high mutation rate of microsatellites—
multiple 2- to 10-bp STR—makes this analysis particularly suited
to detect micro-evolutionary variations of isolates obtained
from different patient’s body sites, and also, from nosocomial
outbreaks involving different patients (van Asbeck et al., 2009).
However, unlike Choi et al. (2018), we incorporated a greater
number of markers in our microsatellite analysis to improve
its discriminatory power. Therefore, according to a method
developed (Sabino et al., 2010) and adopted (Diab-Elschahawi
et al., 2012) to distinguish among C. parapsilosis isolates,
we used a six-marker microsatellite panel for the present
molecular investigation. Our isolates were collected only from
Italian patients, and it was intuitive that coevolution of genetic
markers could provide similar results by any selected typing
method. So, we did not use a multilocus sequence typing or
an automated repetitive sequence-based PCR as an additional
genotyping method (Diab-Elschahawi et al., 2012) but, to
strengthen our molecular investigation, we included random
control isolates obtained from patients of seven countries other
than Italy (Austria, Brazil, Greece, India, Iran, Kuwait, and
the Netherlands).
Of 68 different genotypes identified in our study, two
dominant genotypes were observed in 35 and eight isolates,
respectively, which resulted in two clusters covering only
the isolates from Italy and, importantly, 43 (87.7%) of 49
isolates cross-resistant/NWT to fluconazole and voriconazole
(all harboring the Y132F substitution). Another genotype was
observed in two (4.1%) of 49 isolates. Four other genotypes
were observed only once. Because of microevolution due to
intrinsic instability of microsatellite loci, we considered the
isolates with only minor changes in one of the microsatellite
markers as clonally related though not identical. Thismay suggest
the existence of clonal complexes that exclusively contained
all the 49 fluconazole-resistant Italian isolates. Conversely, all
9 fluconazole-susceptible Italian isolates as well as 56 non-
Italian isolates belonged to unique genotypes, which were
different from the cluster genotypes. As microsatellite genotypes
may acquire resistance through azole exposure at differing
frequencies (Hou et al., 2017), the hypothesis of a link
between genotype and susceptibility to fluconazole (and other
triazoles) is highly verisimilar, as already suggested for C.
parapsilosis (Desnos-Ollivier et al., 2018) and other NCAC
species (Hou et al., 2017). Accordingly, no studies to date
found an association between prior antifungal exposure and
fluconazole-resistant C. parapsilosis BSIs (Govender et al.,
2016; Choi et al., 2018), whereas our registration of prior
antifungal exposure was, unfortunately, incomplete (data not
shown). Thus, it is possible that azole-resistant isolates (in
particular, Y132F isolates) emerged following the overuse of
triazoles for prophylaxis and treatment of invasive Candida
and other fungal infections, and subsequently transmitted via
patient-to patient contact. Two of our patients suffered from
subsequent BSIs with two genotypically identical isolates each—
that both belonged to cluster II in one patient and to cluster
III in the other patient—suggesting an endogenous source
of their infections (Brillowska-Dabrowska et al., 2010). If the
dissemination of Y132F isolates is due to the propensity
to survive outside their host and, hence, in the hospital
environment—perhaps coupled to poor healthcare workers’
adherence to standard contact precautions—this needs to
be determined.
This study has some limitations. As in other NCAC species,
the mechanisms contributing to azole resistance in C. parapsilosis
isolates may be multiple (Pristov and Ghannoum, 2019).
Although an alteration in ERG11 leads to a modification in
the binding site of the enzyme targeted by the azoles, this
alteration can be through either point mutations or upregulation.
However, only one among the C. parapsilosis isolates from a
global antifungal surveillance multicenter study (Castanheira
et al., 2019) overexpressed the ERG11 gene. By contrast, in the
same study, most of the Italian Y132F isolates overexpressed the
MDR1 gene, which encodes for a major-facilitator superfamily
efflux pump (Pristov and Ghannoum, 2019). Thus, we did not
rule out that additional azole resistance mechanisms could have
contributed to the MIC phenotypes observed in our isolates.
Furthermore, we did not explore transcription factors such
as MRR1, which can lead to the upregulation of MDR1, or
UPC2, which can lead to the upregulation of ERG11 (Pristov
and Ghannoum, 2019). However, all but one of the Y132F
isolates from South Korea had the K177N substitution in Mrr1p,
whereas none of the isolates had a missense mutation in Upc2p
(Choi et al., 2018). In practice, our decision of not extending
molecular resistance analyses relies on the undisputable finding
that C. parapsilosis ERG11 alleles carrying Y132F or K143R
substitutions were able to confer elevated azole MICs (≥16-fold)
when expressed in azole-susceptible Saccharomyces cerevisiae,
as shown recently (Singh et al., 2019). Finally, the other aspect
that the Y132F (and K143R) substitutions in clonal isolates may
enable these isolates to acquire a potential for intra-hospital
persistence and/or dissemination also warrants further studies.
CONCLUSION
Fluconazole-resistant clonal isolates of C. parapsilosis harboring
the Y132F substitution were circulating in our hospital. While
this molecular resistance mechanism was apparently dominant,
the clonal lineage of Y132F isolates (i.e., two main clusters of
isolates with identical genotypes that infected different patients)
could indicate either cross-infection among patients or direct
infection of patients—the latter through a possible common
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source—in our hospital. We confirmed the microsatellite-
based typing method as a helpful tool to answer questions of
isolate relatedness. Therefore, detecting the Y132F (and K143R)
substitutions in any bloodstream C. parapsilosis isolate recovered
routinely by means of a rapid molecular assay could be an
attractive way to identify clonal C. parapsilosis isolates in hospital
or clinical settings and, ultimately, prevent their transmission
among patients at risk of BSI.
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